

# Prospective Evaluation of OptiThyDose

NCT06864351

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	University Children's Hospital Basel
<b>Enrollment</b>	150 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Congenital hypothyroidism (CH)
  - Newborns with pathological neonatal screening and confirmation of an increased Thyrotropin (TSH) level in an independent venous blood sample
  - Graves' disease (GD)
  - Children until 18 years with new diagnosis of GD, recurrence of GD, or insufficiently controlled GD under CMZ/MMZ during follow-up according to:
  - Pathological lab values (suppressed TSH, increased thyroid hormone levels, positive Anti-TSH-receptor antibodies)
- ... and 4 more (see full listing online)

### Exclusion (9)

- CH and GD
  - Exclusion of newborns from mothers with GD
  - Exclusion of patients in case of a life-threatening event
  - GD
  - Exclusion of children with known other aetiologies of hyperthyroidism than GD without elevated Anti-TSH-receptor antibodies e.g.:
- ... and 4 more (see full listing online)

## Locations (2 total)

---

Department of Paediatric Endocrinology, Diabetology and Gynaecology, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France

Paediatric Endocrinology and Diabetology, University Children's Hospital Basel (UKBB), Basel, Canton of Basel-City, Switzerland